Latest news with #MedicalDevices
Yahoo
4 days ago
- Business
- Yahoo
Medical Tubing Market worth $18.41 billion by 2030, at a CAGR of 8.0%, says MarketsandMarkets™
Delray Beach, FL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Medical Tubing Market is projected to reach USD 18.41 billion by 2030 from USD 12.53 billion in 2025, at a CAGR of 8.0% during the forecast period. The market for medical tubing is expanding swiftly due to growing worldwide geriatric population, susceptible to chronic conditions such as cardiovascular disorders and kidney failure, propelling demand for medical tubing across markets like catheters, dialysis, and fluid management. Further, growing popularity for less invasive treatments like endoscopy and angioplasty, with their need for flexible and strong tubing, is propelling market growth. Technological advances in extrusion provide high-quality tubing with improved kink resistance, tensile strength, and flexibility. Breakthroughs in material technology, e.g., silicone, polyurethane, and thermoplastic elastomers, enable enhanced performance for numerous applications including drug delivery and respiratory treatment. Additionally, growth in emerging markets in healthcare infrastructure, higher spending on healthcare, and a move towards home healthcare—where light tubing is needed by portable medical devices—helps to fuel the market. The cumulative effect of population aging, the need for minimally invasive surgery, advances in technology, and compliance with regulations helps maintain a growth momentum in the medical tubing market as evolving global healthcare demands persist. Download PDF Brochure: Browse in-depth TOC on 'Medical Tubing Market' 238 - Market Data Tables 53 – Figures 252 - Pages List of Key Players in Medical Tubing Market: Saint-Gobain (France) Freudenberg Medical (US) W. L. Gore & Associates, Inc. (US) The Lubrizol Corporation (US) Nordson Corporation (US) TE Connectivity (Switzerland) Elkem ASA (Norway) Trelleborg AB (Sweden) RAUMEDIC AG (Germany) Teknor Apex (US) Spectrum Plastics Group (US) Zeus Company LLC (US) Drivers, Opportunities and Challenges in Medical Tubing Market: Drivers: Increasing demand for minimally invasive medical procedures Restraint: Limited material compatibility Opportunity: Increasing governmental expenditure for upgrading and developing healthcare infrastructure Challenge: High cost of producing and marketing medical tubing products Get Sample Pages: Key Findings of the Study: Rubber has the largest market share in the medical tubing market during the forecast period. Catheters & cannulas holds the largest share in the medical tubing market during forecast period. In terms of structure, multi-lumen holds the largest share in the medical tubing market during forecast period. North America to be the largest market during the forecast period. Smart tubing in healthcare application are the new advanced tubing systems that have sensors, conductive components, or microfluidic channels integrated into them for enhanced functionality, security, and monitoring. Such tubes are beyond the mere transportation of fluid as they consist of real-time data collection, automation, and enhanced control features, which provide better patient care and procedural efficiency. One of the important features of smart tubing is intrinsic sensors that track parameters such as pressure, temperature, and flow rate to achieve optimal performance in applications like intravenous (IV) therapy, dialysis, and catheterization. Real-time monitoring ensures detection of blockages, leaks, or aberrations, minimizing complications. Certain smart tubing systems also feature RFID or Bluetooth technology for wireless data communication, facilitating remote monitoring in hospital and home healthcare environments. Specialty polymers are growing fastest in the medical tubing market due to their exceptional performance properties, which address the changing demands of the healthcare market. These include thermoplastic elastomers (TPE), polyether ether ketone (PEEK), and fluoropolymers. They provide increased biocompatibility, chemical resistance, and abrasion resistance compared to traditional rubbers and plastics. Their resistance to aggressive sterilization methods, such as autoclaving and gamma radiation, also makes them suitable for use in applications that demand high standards of hygiene, e.g., catheters, intravenous (IV) tubing, and dialysis machines. The increasing demand for minimally invasive surgical procedures has also promoted the use of specialty polymers, as they allow for the creation of flexible, lightweight, and high-performance tubing. Their greater mechanical toughness ensures consistency in rigorous applications, reducing the risk of tube collapse and enhancing patient safety. Specialty polymers are also more resistant to drug interaction and biofouling, ensuring medical liquid integrity as it flows through the tubing. The increasing cases of chronic diseases, such as cardiovascular diseases and diabetes, are propelling higher demand for more advanced medical equipment, hence driving demand for specialty polymer tubing. The fast-paced progress in the field of material science has made it possible to design antimicrobial polymers, thus improving infection prevention in medical facilities. Regulatory bodies like the FDA and EU MDR have also mandated strict standards for medical materials, with a preference for high-performance polymers that are safe and sustainable. As medical device companies and healthcare providers look for materials with better functionality, durability, and regulatory compliance, specialty polymers continue to see accelerated uptake. Their distinct benefits over conventional materials, along with the increasing focus on innovation and patient-centered care, are propelling their highest growth in the medical tubing industry. Drug delivery systems are witnessing the most rapid expansion in the medical tubing industry due to changing healthcare requirements and technological innovation. The increasing incidence of chronic diseases requires effective and targeted drug delivery. Tubing is essential to these systems, allowing drug delivery directly to targeted locations within the body for increased efficacy with reduced side effects. This requirement is further fuelled by the aging population globally, which increasingly needs frequent and advanced medical therapy, much of which involves the use of drug-delivery tubing. In addition, ever-present innovation in drug delivery technology is a key driver. Breakthroughs such as injectable systems, insulin pumps, and inhalers are highly dependent on tailor-made medical tubing to operate efficiently. The evolution of minimally invasive drug delivery systems, including microneedle arrays or linked drug delivery devices, has boosted demand for specialized tubing that can meet complex specifications such as controlled release or high-viscosity biologics. Such innovations enhance patient compliance and comfort, further enhancing adoption. The trend towards personalized medicine drives this growth. Personalized treatments need flexible tubing solutions that can support customized drug formulations and delivery regimens, so drug delivery systems are a dynamic category. Partnerships between medical device and pharma companies are broadening the scope and application of these systems, fueling demand for premium, biocompatible tubing materials such as silicone and fluoropolymers. Get Customization on this Report: The medical tubing market offers various growth opportunities spurred by advances in healthcare technologies, surging demand for minimally invasive procedures, and the high incidence of chronic diseases. The greatest opportunity comes in the increasing usage of home healthcare and wearable medical devices like insulin pumps and portable oxygen therapy that need top-grade, flexible, and robust tubing. Moreover, the growing application of biologics generate a need for specialized tubing solutions that provide the safe and accurate delivery of sensitive drugs. Advances in material science, such as biodegradable and antimicrobial tubing, provide opportunities to improve patient safety and minimize hospital-acquired infections. The incorporation of intelligent technologies, including sensors on tubing for the real-time measurement of fluid flow and pressure, is another area with great promise, enhancing the accuracy and efficiency of treatment. Asian-Pacific and Latin America provide compelling opportunities for growth that are accompanied by building up health care infrastructures and further investments by the governments in the manufacture of medical devices. Additionally, the movement toward green and recyclable medical materials concurs with world environmental campaigns to support the design of green medical tubing. With ongoing needs for healthcare, on-going research and advancements in technology will create increased prospects for the medical tubing market. Saint-Gobain (France) is a French multinational corporation dedicated to industrial construction materials and services manufacturing and distribution. The medical tubing business segment operates under its subsidiary Saint-Gobain Performance Plastics which trades as Saint-Gobain Life Sciences. The division of Saint-Gobain Performance Plastics develops numerous high-performance materials and component products including medical tubing products for medical applications in healthcare sectors. Freudenberg Medical (US), a division of Germany-based Freudenberg Group, develops medical components and devices while also designing and manufacturing them. By operating under Freudenberg Group's specialties business area the company delivers catheters, hypotubes and balloons with minimally invasive procedure coating solutions alongside steerable shafts, engineered needles and precision-molded components and medical silicone and plastic tubing. Freudenberg Medical operates 11 manufacturing facilities through corporate branches located across the Americas, Europe and Asia servicing Costa Rica, India, China, Ireland, Singapore, the United States and Germany. Browse Adjacent Markets Specialty Chemicals Market Research Reports & Consulting Related Reports: Chillers Market Lubricants Market Global Chemical Industry Outlook 2025 Wood Coatings Market Cooling Fabrics Market CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development
TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, a state-of-the-art facility designed to help OEM partners rapidly prototype, test, and optimize textile-based medical materials. Located in Taunton, UK, the Innovation Lab provides Corza Medical's partners with a collaborative, hands-on environment where concepts can be transformed into validated prototypes within days versus weeks. Equipped with advanced analytical testing capabilities and supported by a highly experienced team of textile development specialists, the lab marks a significant advancement in reducing development cycles and accelerating time to market. "The Innovation Lab represents our commitment to OEM partners who demand both speed, precision, and quality," said James Getty, Senior Vice President and General Manager of Biomedical Textiles at Corza Medical. "By bringing prototyping, testing, and engineering expertise together in one place, we're enabling our customers to move from concept to commercialization faster than ever before." The facility supports a wide range of textile-based medical components, using high-performance absorbable and non-absorbable materials including Nylon, Silk, Polypropylene, Polyester, and Ultra-High-Molecular-Weight Polyethylene (UHMWPE). From advanced constructs to simple suture assemblies, the lab is equipped to meet a variety of OEM needs. Corza Medical delivers one of the most comprehensive material science portfolios in the industry, enabling advanced solutions in medical attachment, suturing, and connectivity. Key capabilities of the Innovation Lab include: Rapid Prototyping of textile structures, including complex configurations such as loops, splices, bifurcations, embroidery, and round-flat-round transitions Suture Assembly Services including knot tying, cut-to-length, stitching, sewing, and packaging for device-ready components Prototype-to-Scale Support to transition early-stage designs into commercially scalable solutions In-House Testing Services including tensile strength, elongation, surface imaging, thermal analysis, and moisture response Custom Engineering Collaboration to troubleshoot and refine device designs in real time Confidential, Commitment-Free Engagements for early-stage exploration, feasibility validation, or competitive benchmarking Each Innovation Lab engagement is fully customizable and results in a verified prototype for validation, supporting test data, and recommendations for next steps. 'This isn't just a lab. It's an accelerator for innovation,' said Tariq Abalis, Head of Global Commercial of Biomedical Textiles at Corza Medical. 'Whether our partners are optimizing an existing product or exploring a new concept, we're here to help them move faster with more confidence." The Corza Medical Biomedical Textiles Innovation Lab is now accepting inquiries and scheduling lab collaborations. To learn more or schedule a session, visit: Media Contact:Suzanne Hatcher Global Communicationsmedia@ Customer Contact:Amy JearyProduct Marketing Manager, Biomedical Textiles, Corza About Corza MedicalCorza Medical is a leading global medical technology company that specializes in innovative surgical solutions and technologies. With a global team of approximately 3,000 employees supporting clinicians, distributor partners and medical device companies worldwide, Corza provides healthcare professionals with a platform of surgical technologies featuring many industry-leading brands, including Quill® barbed sutures, Sharpoint® Plus and Look™ surgical sutures, Katena® reusable and Blink™ single-use ophthalmic instruments, Barron corneal transplant devices, Sharpoint® microsurgical knives and the TachoSil® fibrin sealant patch. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033
Innovation now defines the organ care products market. Advanced perfusion and portable systems are actively expanding the donor organ pool, tackling immense waiting lists driven by chronic diseases and dramatically improving success rates for vital transplants. Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global organ care products market was valued at US$ 199.20 million in 2024 and is expected to reach US$ 812.12 million by 2033, growing at a CAGR of 16.90% during the forecast period 2025–2033. The current scenario in the organ care products market is one of explosive growth, fueled by the twin engines of unprecedented global demand and transformative technology. In 2024, the U.S. performed a record 48,149 transplants, yet this barely meets the need, as regions like Eurotransplant still have over 13,570 patients on waiting lists. This profound supply-demand imbalance is accelerating a fundamental shift away from traditional static cold storage towards advanced perfusion and assessment systems. These technologies are directly addressing the critical issue of organ non-utilization, aiming to convert a portion of the thousands of organs discarded annually into life-saving opportunities, thereby changing the entire calculus of transplantation. Request Sample Pages: This evolution is being aggressively capitalized upon by key industry players through strategic expansion and is buoyed by substantial investment. Recent developments, such as Paragonix's EU MDR certification for five devices in March 2025 and its rapid U.S. commercial expansion, highlight a fierce race to capture market share. The market's momentum is further underwritten by significant capital influx, from government initiatives like the $67 million allocated for U.S. transplant system modernization in FY2025 to targeted research funding from organizations like Enduring Hearts. The current scenario is therefore not just about growth, but about a well-funded, strategic push to commercialize innovation on a global scale. Key Findings in Organ Care Products Market Market Forecast (2033) US$ 812.12 million CAGR 16.90% Largest Region (2024) North America (56%) By Organ Type Kidney (28%) By Product Type Trolly (53%) Top Drivers Rising global incidence of chronic diseases fuels organ transplant demand. Technological advancements in organ preservation systems improve transplant success rates. Favorable reimbursement policies encourage organ transplant procedures, boosting market growth. Top Trends Emergence of normothermic machine perfusion for real-time organ function assessment. Development of smaller, portable organ preservation devices for easier transport. Focus on developing organ-specific preservation solutions for better patient outcomes. Top Challenges Complex ethical and logistical hurdles in organ procurement and allocation. Unprecedented Transplant Volumes Are Fueling Robust Market Expansion and Demand The foundational driver for the organ care products market is the sheer volume of surgical procedures, which continued its upward trajectory through 2024. In the United States alone, a record of over 48,000 organ transplants were performed. This milestone was confirmed with a final tally of 48,149 procedures for the year, marking the first time the nation has exceeded this figure. This represents an impressive average of 132 organ transplants performed each day in the U.S. throughout 2024. Critically, 2024 marked the 14th consecutive year of growth in the number of organs recovered for transplants in the U.S., signaling a sustained and reliable increase in the core activity that underpins the market. This trend is not isolated; globally, organ transplantation activities saw a notable increase in 2023, which has set a strong precedent for continued growth in 2024 and beyond. In Europe, the eight Eurotransplant countries allocated 7,150 organs from deceased donors in 2024, while in China, a remarkable 24,684 transplant surgeries were performed during the same year, showcasing the truly global nature of this expansion. The Critical Role of Organ Procurement in Shaping Market Dynamics The availability and procurement of donor organs represent the starting point for the entire transplantation value chain, directly influencing the organ care products market. In the United States, 55 dedicated organ procurement organizations (OPOs) were operational as of October 2024, forming the backbone of the recovery network. In 2024, these U.S. OPOs successfully recovered over 45,000 organs for transplant procedures. This was made possible by the 16,989 Americans who became deceased organ donors, a testament to growing awareness and consent. These efforts were supplemented by more than 7,000 living donors in the U.S. in 2024. An interesting demographic trend shows that nearly 8,200 of the deceased donors in the U.S. in 2024 were aged 55 and older, highlighting the expanding criteria for donation. In the United Kingdom, from April 2023 to March 2024, there were 1,510 deceased organ donors and 938 living organ donors. Across the Eurotransplant region, organs were sourced from 2,181 deceased donors in 2024. Meanwhile, China recorded 6,744 cases of organ donations in 2024, with the number of registered organ donors soaring to over 7.05 million by early 2025, indicating massive future potential. Organ-Specific Procedural Growth Creates Niche Opportunities Within the Market A deeper analysis of procedural data reveals that growth is not uniform across all organ types, creating distinct and lucrative opportunities within the organ care products market for specialized preservation technologies. In the United States during 2024, cardiac procedures were significant, with 4,572 heart transplants performed. Thoracic procedures were also prominent, as the number of lung transplants reached 3,340. Abdominal transplants, which constitute the largest segment, saw a total of 11,458 liver transplants and an impressive 27,759 kidney transplants performed in the U.S. in 2024. This high volume in renal transplantation underscores the demand for reliable kidney preservation solutions. Furthermore, specialized procedures are gaining traction; in the UK, for instance, 65 Donation after Circulatory Death (DCD) heart transplants took place in the 2023/24 period, a complex procedure that relies heavily on advanced preservation technology to ensure viability. Diverse Regional Landscapes Present Unique Challenges and Growth Avenues The global organ care products market is characterized by significant regional variations in infrastructure, regulatory frameworks, and donation patterns. China's market, for example, is notable for its scale; as of early 2025, there have been more than 58,000 cumulative organ donations to date. The country has also recorded over 63,000 body donations and 110,000 corneal donations as of 2025, pointing to a well-established and growing donation culture. In the UK, the data from 2023-2024 provides a detailed look at the procurement funnel, with 772 donors after brain death (DBD) and 738 donors after circulatory death (DCD). That year, there were 6,794 potential deceased organ donors identified in the UK, of whom 6,421 were formally referred as potential donors. From that pool, donation requests were made to families in 3,107 cases, ultimately resulting in 1,880 consented donors, illustrating the multi-step process where advanced care technology can play a role in boosting confidence and consent. Groundbreaking Product Innovation and Regulatory Wins Propel Market Leaders Forward Innovation is the lifeblood of the organ care products market, with regulatory approvals serving as key milestones that unlock new commercial opportunities. In October 2024, Paragonix Technologies achieved a major milestone with FDA 510(k) clearance for its KidneyVault portable renal perfusion system. This strategic clearance solidified Paragonix as the only company possessing U.S. regulatory clearances for advanced preservation devices for all five solid organs used in transplants. Earlier in the year, in June 2024, the company launched its PancreasPak, the world's first FDA-cleared preservation device for donor pancreases, with pre-orders beginning on June 27, 2024, and full commercial availability planned for September 1, 2024. In April 2024, Paragonix also announced the full U.S. commercial launch of its BAROguard Donor Lung Preservation System. During its limited market release, 5 of the top U.S. thoracic transplant centers had already deployed the BAROguard System. The momentum continued into 2025, when Paragonix received EU MDR approval for five of its organ preservation devices in March. These specific product approvals stood out in a year where the FDA approved a total of just 21 medical devices overall in 2024. Strong Financial Performance and Strategic Investments Signal a Healthy Marketplace The financial health and strategic initiatives of key industry players in the organ care products market provide compelling evidence of a vibrant and growing market. XVIVO Perfusion reported strong results for 2024, with net sales amounting to SEK 822.4 million for the full year. The fourth quarter of 2024 was particularly robust, with net sales reaching SEK 227.6 million. The company's profitability was also solid, with an operating income (EBIT) for Q4 2024 of SEK 15.5 million and an operating income before depreciation and amortization (EBITDA) of SEK 51.9 million. Strong operational execution led to a cash flow from operating activities of SEK 62.1 million in Q4 2024, and the company posted a net profit for the full year 2024 of SEK 172.2 million. On the utilization front, Paragonix preservation devices have been used in over 10,000 transplant cases globally as of March 2025, demonstrating deep market penetration. Specifically, the Paragonix SherpaPak and LUNGguard systems are utilized at over 150 transplant centers globally, including over 40 transplant centers in the EU, highlighting the company's expanding international footprint. Modernization Initiatives and Research Funding Pave the Way for Future Growth Substantial government and institutional investments in research and system modernization are creating a fertile ground for the future growth of the organ care products market. The U.S. Senate Appropriations Committee has included a significant $67 million in funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative for fiscal year 2025. This represents a $13 million increase over FY 2024 levels. The FY24 funding package had already included an additional $23 Million for the HRSA OPTN Modernization Initiative, bringing the total for that year to $52 Million. In 2024, the Mid-America Transplant Foundation's Clinical Innovation Fund began offering awards of up to $150,000 per year for three years to spur new research. The American Society of Transplantation (AST) is furthering this by offering a research grant of $75,000 for one year, with a term starting January 1, 2025. The International Society for Heart & Lung Transplantation is offering a grant of up to $75,000 for research into DCD heart transplantation, with recipients to be announced in January 2025, and a second grant of up to $37,500 for acellular Ex Vivo Lung Perfusion (EVLP) research. In 2024, the Scandiatransplant Research grant also supported two projects with 100,630 DKK and 260,000 DKK, respectively. Need a Customized Version? Request It Now: Addressing Organ Utilization and Waiting Lists Remains a Core Market Imperative The persistent challenges of organ non-utilization and extensive patient waiting lists serve as powerful catalysts for the organ care products market, driving the need for technologies that can preserve, assess, and improve marginal organs. In 2024, a concerning 9,275 recovered kidneys in the U.S. were ultimately not used for transplant, continuing a trend that highlights a critical gap between recovery and utilization. To combat this, OPOs have hosted eleven Transplant Growth Collaborations over the past year to share successful practices. Advanced perfusion is emerging as a key solution; a 2024 study of 803 transplantations, of which 174 received Normothermic Machine Perfusion (NMP), showed NMP was associated with a reduced need for early relaparotomy in liver transplants. Another 2024 study involving 118 NMP-treated livers matched with 236 preserved with static cold storage, and a cohort matching 37 NMP-DCD livers with 74 using static cold storage, are providing crucial data on efficacy. Global Organ Care Products Market Major Players: Bridge to Life Ltd. TransMedics Inc. Organ Recovery system XVIVO Preservation Solution Inc. Paragonix technologies and IGL OrganOx Limited Other Prominent Players Key Market Segmentation: By Organ Type Kidney Liver Heart Lungs Others By Product Type Trolly Portable By Region North America Europe Asia Pacific Middle East Africa South America Request a Personalized Report Walkthrough with Our Research Team: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Europe Syringe Infusion Pump Market Analysis Report 2025-2030, with Key Player Profiles for B. Braun, Baxter, Fresenius Kabi, Micrel Medical Devices, CODAN, Acromed, ICU Medical, Terumo, and Moog
The European Syringe Infusion Pump Market, valued at USD 465.1M in 2024, is projected to reach USD 729.5M by 2030, growing at a 7.90% CAGR. This growth is driven by rising preterm births, chronic diseases, and advanced technology adoption. Leading segments include pediatrics/neonatology and hospitals. Germany holds the largest market share, with rapid growth expected in home care. The report offers detailed market analysis, future trends, and actionable recommendations for strategic decision-making. European Syringe Infusion Pump Market Dublin, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The "Europe Syringe Infusion Pump Market Size, Share & Trends Analysis Report by Disease Indication (Chemotherapy, Gastroenterology, Hematology), End-use, Country with Growth Forecasts, 2025-2030" has been added to European Syringe Infusion Pump Market is projected to grow from USD 465.1 million in 2024 to USD 729.5 million by 2030, at a CAGR of 7.9%. This growth is fueled by the increasing incidence of preterm births, the rising prevalence of chronic diseases, and the drive towards advanced technology in healthcare equipment. Additionally, the surge in cancer cases and diabetes diagnoses, along with the rise in intensive care unit admissions, contribute significantly to the market's expansion. The launch of innovative products featuring real-time monitoring capabilities is set to enhance product adoption in hospitals and healthcare facilities. Advancements propelled by research-based developments, regulatory mandates for device safety and quality, and the rising demand for controlled medication delivery and precision dosing in critical care applications present substantial growth opportunities. Europe Syringe Infusion Pump Market Report Highlights Pediatrics/Neonatology Segment: Led the market with a 26.2% revenue share in 2024, reflecting the role of syringe infusion pumps in controlled drug delivery for newborns. Chemotherapy Segment: Expected to witness the fastest CAGR through 2030, driven by increasing chronic disease incidences and the merging of palliative care with cancer treatments. Hospitals Segment: Accounted for the largest market revenue share in 2024, highlighting the need for precision dosing and controlled drug delivery in various treatments. Home Care Segment: Projected to grow at the fastest CAGR from 2025 to 2030. Germany: Dominated the market with the largest revenue share in 2024 due to the presence of manufacturers and extensive applications in intensive care, chemotherapy, and pain management. This report addresses: Market insights for informed decision-making Market estimates and forecasts from 2018 to 2030 Identifying growth opportunities and trends Segment and regional revenue forecasts Analysis of competition strategies and market share Innovative product listings to keep in touch with market advancements Why Should You Buy This Report? Comprehensive Market Analysis: Gain insights into key market regions and segments. Competitive Landscape: Understand the market presence of leading players. Future Trends: Discover trends and drivers shaping the market's future. Actionable Recommendations: Leverage insights to explore new revenue streams and inform strategic business decisions. Companies Featured The major companies featured in this Europe Syringe Infusion Pump market report include: B. Braun SE Baxter BD Fresenius Kabi AG Micrel Medical Devices SA CODAN Companies Arcomed ICU Medical, Inc. (Smiths Medical) Terumo Corporation Moog Inc. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $465.1 Million Forecasted Market Value (USD) by 2030 $729.5 Million Compound Annual Growth Rate 7.9% Regions Covered Europe Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Disease indication outlook2.2.2. End use outlook2.2.3. Country outlook2.3. Competitive InsightsChapter 3. Europe Syringe Infusion Pumps Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.3. Europe Syringe Infusion Pumps Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. Europe Syringe Infusion Pumps Market: Disease Indication Estimates & Trend Analysis4.1. Disease Indication Segment Dashboard4.2. Europe Syringe Infusion Pumps Market: Disease Indication Movement Analysis4.3. Europe Syringe Infusion Pumps Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)4.4. Chemotherapy4.5. Diabetes4.6. Gastroenterology4.7. Analgesia/Pain Management4.8. Pediatrics/Neonatology4.9. Hematology4.10. OthersChapter 5. Europe Syringe Infusion Pumps Market: End Use Estimates & Trend Analysis5.1. End Use Segment Dashboard5.2. Europe Syringe Infusion Pumps Market: End Use Movement Analysis5.3. Europe Syringe Infusion Pumps Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)5.4. Hospitals5.5. Homecare5.6. Others (ASC, Nursing Homes, Rehabilitation Centers)Chapter 6. Europe Syringe Infusion Pumps Market: Country Estimates & Trend Analysis6.1. Country Market Dashboard6.2. Country Market Share Analysis, 2024 & 20306.3. Europe Syringe Infusion Pumps Market, By Country: Key TakeawaysChapter 7. Competitive Landscape7.1. Recent Developments & Impact Analysis, By Key Market Participants7.2. Company/Competition Categorization7.3. Vendor Landscape B. Braun SE Baxter BD Fresenius Kabi AG Micrel Medical Devices SA CODAN Companies Arcomed ICU Medical, Inc. (Smiths Medical) Terumo Corporation Moog Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Syringe Infusion Pump Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-07-2025
- Health
- Yahoo
North American capsule endoscopy market seeks minimally invasive procedures
Capsule endoscopy devices, which employ tiny, ingestible camera-equipped capsules to capture and transmit images of the digestive tract, are becoming increasingly popular for the diagnosis of gastrointestinal disorders. Capsule endoscopy devices have some advantages over traditional endoscopes, such as improved patient comfort and fewer complications, and are gaining traction in North America. According to projections from GlobalData, the capsule endoscopy market is expected to see a compound annual growth rate (CAGR) of 6.2% between 2024 and 2034. Within the North American region, Canada is anticipated to see the strongest growth at 7% CAGR, followed by Mexico with 6.2% and the US with 6.1%. The US makes up the largest portion of the North American capsule endoscopy market. Market growth in North America is largely driven by the increasing population, the rising incidence of gastrointestinal diseases and a growing preference among patients and providers for minimally invasive procedures. Technological advancements aimed at enhancing imaging quality and the control capabilities of these capsule devices are further accelerating market adoption. Capsule endoscopy involves the utilisation of small medical devices, typically weighing between 1.9 grams and 4 grams. These capsules are equipped with a battery, light source, camera and transmitter. Once ingested by the patient, the capsule travels through the digestive tract, transmitting detailed images from the oesophagus, stomach and small bowel to an external receiver. The market is growing as new applications for capsule endoscopy emerge, replacing traditional endoscopic procedures. Medtronic holds a dominant position in North America, with 89.4% of market share. Continued innovation and expanded indications for capsule endoscopy are expected to sustain robust market growth throughout the forecast period. "North American capsule endoscopy market seeks minimally invasive procedures" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.